EMA Authorised: Okedi (risperidone) — Laboratorios Farmacéuticos Rovi, S.A.

View source ↗

Summary

The European Medicines Agency authorised Okedi, a risperidone product, for the treatment of schizophrenia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• Okedi (risperidone)

Snippet

Status: Authorised. Therapeutic area: Schizophrenia. MAH: Laboratorios Farmacéuticos Rovi, S.A.. Decision date: 11/10/2025